P16 gene deletion detection probe (P16 (CDK2NA)/CEP9)

P16(CDKN2A) Gene Deletion Probe Detection Kit - 100µL/10 Tests

CDKN2A loss has been shown to be a significant event in a number of cancer types. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. In majority of cases CDKN2A is inactivated by homozygous deletions. One of the mechanisms by which loss of CDKN2A can occur is by hypermethylation of the promoter region for the gene. However, the prognostic impact of promoter hypermethylation has been relatively ambiguous.

Many studies have suggesting poorer prognostic outcome for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator. Additionally, CDKN2A (p16) expression is a surrogate marker for HPV infection. As such, CDKN2A expression is prognostic in Oropharyngeal and probably also non-oropharyngeal head and neck squamous cell carcinomas.

Product Introduction
The kit uses orange fluorescein-labeled P16 probe and green fluorescein-labeled CEP9 probe to bind P16/CEP9 probe to the target detection site by in situ hybridization.

Product Main Components

The kit consists of P16/CEP9 dual color probe

Applicable Instruments

Fluorescence microscopy imaging systems, including fluorescence microscopy and filter sets suitable for DAPI (367/452), Green (495/517), and Orange (547/565).